NO330296B1 - Opplosning av N-[O-(p-pivaloyloksybenzensulfonylamino)-benzoyl]glycinmononatriumsalt-tetrahydrat og medisinsk produkt - Google Patents
Opplosning av N-[O-(p-pivaloyloksybenzensulfonylamino)-benzoyl]glycinmononatriumsalt-tetrahydrat og medisinsk produkt Download PDFInfo
- Publication number
- NO330296B1 NO330296B1 NO20013223A NO20013223A NO330296B1 NO 330296 B1 NO330296 B1 NO 330296B1 NO 20013223 A NO20013223 A NO 20013223A NO 20013223 A NO20013223 A NO 20013223A NO 330296 B1 NO330296 B1 NO 330296B1
- Authority
- NO
- Norway
- Prior art keywords
- solution
- compound
- sodium hydroxide
- water
- added
- Prior art date
Links
- 229940127554 medical product Drugs 0.000 title claims description 16
- 125000003236 benzoyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C(*)=O 0.000 title claims description 4
- -1 p-pivaloyloxybenzenesulfonylamino Chemical group 0.000 title description 4
- NGXWUVUVHAXVDY-UHFFFAOYSA-M sodium 2-aminoacetate tetrahydrate Chemical compound O.O.O.O.[Na+].NCC([O-])=O NGXWUVUVHAXVDY-UHFFFAOYSA-M 0.000 title description 2
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 claims abstract description 123
- KWYUFKZDYYNOTN-UHFFFAOYSA-M Potassium hydroxide Chemical compound [OH-].[K+] KWYUFKZDYYNOTN-UHFFFAOYSA-M 0.000 claims abstract description 60
- 239000003002 pH adjusting agent Substances 0.000 claims abstract description 23
- 239000001488 sodium phosphate Substances 0.000 claims abstract description 19
- RYFMWSXOAZQYPI-UHFFFAOYSA-K trisodium phosphate Chemical compound [Na+].[Na+].[Na+].[O-]P([O-])([O-])=O RYFMWSXOAZQYPI-UHFFFAOYSA-K 0.000 claims abstract description 19
- 229910000406 trisodium phosphate Inorganic materials 0.000 claims abstract description 19
- 235000019801 trisodium phosphate Nutrition 0.000 claims abstract description 19
- QBIHEHITTANFEO-UHFFFAOYSA-N sodium;tetrahydrate Chemical compound O.O.O.O.[Na] QBIHEHITTANFEO-UHFFFAOYSA-N 0.000 claims abstract description 5
- 150000001875 compounds Chemical group 0.000 claims description 83
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 52
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 49
- 239000000203 mixture Substances 0.000 claims description 39
- 239000003960 organic solvent Substances 0.000 claims description 21
- 238000002360 preparation method Methods 0.000 claims description 19
- 239000002904 solvent Substances 0.000 claims description 18
- 230000001154 acute effect Effects 0.000 claims description 6
- 208000019693 Lung disease Diseases 0.000 claims description 5
- 229940079593 drug Drugs 0.000 claims description 5
- 239000003814 drug Substances 0.000 claims description 5
- 239000003795 chemical substances by application Substances 0.000 claims description 4
- 239000004471 Glycine Substances 0.000 claims description 2
- 125000003158 alcohol group Chemical group 0.000 claims 1
- 239000000243 solution Substances 0.000 description 72
- 239000007864 aqueous solution Substances 0.000 description 42
- 238000003756 stirring Methods 0.000 description 19
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 16
- 229930195725 Mannitol Natural products 0.000 description 16
- 239000000594 mannitol Substances 0.000 description 16
- 235000010355 mannitol Nutrition 0.000 description 16
- 238000007796 conventional method Methods 0.000 description 15
- 239000000047 product Substances 0.000 description 13
- 229940126601 medicinal product Drugs 0.000 description 12
- 239000000725 suspension Substances 0.000 description 12
- 238000000034 method Methods 0.000 description 9
- 239000007924 injection Substances 0.000 description 8
- 238000002347 injection Methods 0.000 description 8
- CDBYLPFSWZWCQE-UHFFFAOYSA-L Sodium Carbonate Chemical compound [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 description 7
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 6
- 238000003860 storage Methods 0.000 description 6
- 239000003708 ampul Substances 0.000 description 5
- BNIILDVGGAEEIG-UHFFFAOYSA-L disodium hydrogen phosphate Chemical compound [Na+].[Na+].OP([O-])([O-])=O BNIILDVGGAEEIG-UHFFFAOYSA-L 0.000 description 5
- DGLRDKLJZLEJCY-UHFFFAOYSA-L disodium hydrogenphosphate dodecahydrate Chemical compound O.O.O.O.O.O.O.O.O.O.O.O.[Na+].[Na+].OP([O-])([O-])=O DGLRDKLJZLEJCY-UHFFFAOYSA-L 0.000 description 4
- 239000012153 distilled water Substances 0.000 description 4
- 238000004108 freeze drying Methods 0.000 description 4
- 238000011835 investigation Methods 0.000 description 4
- 239000000872 buffer Substances 0.000 description 3
- 238000000354 decomposition reaction Methods 0.000 description 3
- 238000004811 liquid chromatography Methods 0.000 description 3
- 238000004519 manufacturing process Methods 0.000 description 3
- 238000002156 mixing Methods 0.000 description 3
- 229910000029 sodium carbonate Inorganic materials 0.000 description 3
- 239000011780 sodium chloride Substances 0.000 description 3
- 235000002639 sodium chloride Nutrition 0.000 description 3
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 2
- MBBZMMPHUWSWHV-BDVNFPICSA-N N-methylglucamine Chemical compound CNC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO MBBZMMPHUWSWHV-BDVNFPICSA-N 0.000 description 2
- KIHNJWGKOCEFQC-UHFFFAOYSA-N O.O.O.O.O.O.O.O.O.O.O.O.[Na].[Na].[Na] Chemical compound O.O.O.O.O.O.O.O.O.O.O.O.[Na].[Na].[Na] KIHNJWGKOCEFQC-UHFFFAOYSA-N 0.000 description 2
- PLHREJBSQUSUCW-UHFFFAOYSA-M Sivelestat sodium hydrate Chemical compound O.O.O.O.[Na+].C1=CC(OC(=O)C(C)(C)C)=CC=C1S(=O)(=O)NC1=CC=CC=C1C(=O)NCC([O-])=O PLHREJBSQUSUCW-UHFFFAOYSA-M 0.000 description 2
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 2
- DKGAVHZHDRPRBM-UHFFFAOYSA-N Tert-Butanol Chemical compound CC(C)(C)O DKGAVHZHDRPRBM-UHFFFAOYSA-N 0.000 description 2
- 230000033228 biological regulation Effects 0.000 description 2
- 238000002474 experimental method Methods 0.000 description 2
- 239000000706 filtrate Substances 0.000 description 2
- 238000009472 formulation Methods 0.000 description 2
- 238000010438 heat treatment Methods 0.000 description 2
- 239000012907 medicinal substance Substances 0.000 description 2
- 229960003194 meglumine Drugs 0.000 description 2
- 238000007911 parenteral administration Methods 0.000 description 2
- 239000000546 pharmaceutical excipient Substances 0.000 description 2
- 239000000825 pharmaceutical preparation Substances 0.000 description 2
- 229940127557 pharmaceutical product Drugs 0.000 description 2
- BWHMMNNQKKPAPP-UHFFFAOYSA-L potassium carbonate Chemical compound [K+].[K+].[O-]C([O-])=O BWHMMNNQKKPAPP-UHFFFAOYSA-L 0.000 description 2
- 230000000630 rising effect Effects 0.000 description 2
- 239000007787 solid Substances 0.000 description 2
- LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 2
- OWEGMIWEEQEYGQ-UHFFFAOYSA-N 100676-05-9 Natural products OC1C(O)C(O)C(CO)OC1OCC1C(O)C(O)C(O)C(OC2C(OC(O)C(O)C2O)CO)O1 OWEGMIWEEQEYGQ-UHFFFAOYSA-N 0.000 description 1
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 1
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Natural products NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
- GUBGYTABKSRVRQ-PICCSMPSSA-N Maltose Natural products O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@@H](CO)OC(O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-PICCSMPSSA-N 0.000 description 1
- 102000016387 Pancreatic elastase Human genes 0.000 description 1
- 108010067372 Pancreatic elastase Proteins 0.000 description 1
- 241000220317 Rosa Species 0.000 description 1
- TVXBFESIOXBWNM-UHFFFAOYSA-N Xylitol Natural products OCCC(O)C(O)C(O)CCO TVXBFESIOXBWNM-UHFFFAOYSA-N 0.000 description 1
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
- GUBGYTABKSRVRQ-QUYVBRFLSA-N beta-maltose Chemical compound OC[C@H]1O[C@H](O[C@H]2[C@H](O)[C@@H](O)[C@H](O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@@H]1O GUBGYTABKSRVRQ-QUYVBRFLSA-N 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- 239000006172 buffering agent Substances 0.000 description 1
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 1
- 239000003638 chemical reducing agent Substances 0.000 description 1
- 230000000694 effects Effects 0.000 description 1
- 239000000839 emulsion Substances 0.000 description 1
- 238000011049 filling Methods 0.000 description 1
- 239000012530 fluid Substances 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 238000001802 infusion Methods 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 238000001990 intravenous administration Methods 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 210000004072 lung Anatomy 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- HEBKCHPVOIAQTA-UHFFFAOYSA-N meso ribitol Natural products OCC(O)C(O)C(O)CO HEBKCHPVOIAQTA-UHFFFAOYSA-N 0.000 description 1
- 239000002504 physiological saline solution Substances 0.000 description 1
- 229910000027 potassium carbonate Inorganic materials 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 239000012047 saturated solution Substances 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 229910000030 sodium bicarbonate Inorganic materials 0.000 description 1
- 235000017557 sodium bicarbonate Nutrition 0.000 description 1
- 239000008247 solid mixture Substances 0.000 description 1
- 239000000600 sorbitol Substances 0.000 description 1
- 235000010356 sorbitol Nutrition 0.000 description 1
- 230000006641 stabilisation Effects 0.000 description 1
- 238000013112 stability test Methods 0.000 description 1
- 238000011105 stabilization Methods 0.000 description 1
- 239000003381 stabilizer Substances 0.000 description 1
- 239000012258 stirred mixture Substances 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- ASTWEMOBIXQPPV-UHFFFAOYSA-K trisodium;phosphate;dodecahydrate Chemical compound O.O.O.O.O.O.O.O.O.O.O.O.[Na+].[Na+].[Na+].[O-]P([O-])([O-])=O ASTWEMOBIXQPPV-UHFFFAOYSA-K 0.000 description 1
- 210000003462 vein Anatomy 0.000 description 1
- 239000000811 xylitol Substances 0.000 description 1
- 235000010447 xylitol Nutrition 0.000 description 1
- HEBKCHPVOIAQTA-SCDXWVJYSA-N xylitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)CO HEBKCHPVOIAQTA-SCDXWVJYSA-N 0.000 description 1
- 229960002675 xylitol Drugs 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C311/00—Amides of sulfonic acids, i.e. compounds having singly-bound oxygen atoms of sulfo groups replaced by nitrogen atoms, not being part of nitro or nitroso groups
- C07C311/30—Sulfonamides, the carbon skeleton of the acid part being further substituted by singly-bound nitrogen atoms, not being part of nitro or nitroso groups
- C07C311/37—Sulfonamides, the carbon skeleton of the acid part being further substituted by singly-bound nitrogen atoms, not being part of nitro or nitroso groups having the sulfur atom of at least one of the sulfonamide groups bound to a carbon atom of a six-membered aromatic ring
- C07C311/38—Sulfonamides, the carbon skeleton of the acid part being further substituted by singly-bound nitrogen atoms, not being part of nitro or nitroso groups having the sulfur atom of at least one of the sulfonamide groups bound to a carbon atom of a six-membered aromatic ring having sulfur atoms of sulfonamide groups and amino groups bound to carbon atoms of six-membered rings of the same carbon skeleton
- C07C311/44—Sulfonamides, the carbon skeleton of the acid part being further substituted by singly-bound nitrogen atoms, not being part of nitro or nitroso groups having the sulfur atom of at least one of the sulfonamide groups bound to a carbon atom of a six-membered aromatic ring having sulfur atoms of sulfonamide groups and amino groups bound to carbon atoms of six-membered rings of the same carbon skeleton having the nitrogen atom of at least one of the sulfonamide groups bound to a carbon atom of a six-membered aromatic ring
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/63—Compounds containing para-N-benzenesulfonyl-N-groups, e.g. sulfanilamide, p-nitrobenzenesulfonyl hydrazide
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
- A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
- A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/02—Inorganic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/08—Solutions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2000195853 | 2000-06-29 | ||
| JP2000195852 | 2000-06-29 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| NO20013223D0 NO20013223D0 (no) | 2001-06-27 |
| NO20013223L NO20013223L (no) | 2001-12-31 |
| NO330296B1 true NO330296B1 (no) | 2011-03-21 |
Family
ID=26594951
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| NO20013223A NO330296B1 (no) | 2000-06-29 | 2001-06-27 | Opplosning av N-[O-(p-pivaloyloksybenzensulfonylamino)-benzoyl]glycinmononatriumsalt-tetrahydrat og medisinsk produkt |
Country Status (19)
| Country | Link |
|---|---|
| US (1) | US6552082B2 (es) |
| EP (1) | EP1166773B1 (es) |
| KR (1) | KR100725076B1 (es) |
| CN (1) | CN1263736C (es) |
| AT (1) | ATE259218T1 (es) |
| AU (1) | AU782838B2 (es) |
| BR (1) | BR0102604B1 (es) |
| CA (1) | CA2351273C (es) |
| DE (1) | DE60101979T2 (es) |
| DK (1) | DK1166773T3 (es) |
| ES (1) | ES2215856T3 (es) |
| HU (1) | HUP0102699A2 (es) |
| MX (1) | MXPA01006698A (es) |
| NO (1) | NO330296B1 (es) |
| NZ (1) | NZ512486A (es) |
| PT (1) | PT1166773E (es) |
| RU (1) | RU2272623C2 (es) |
| TR (1) | TR200400585T4 (es) |
| TW (1) | TWI246925B (es) |
Families Citing this family (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2416600A1 (en) * | 2000-07-24 | 2003-01-20 | Ono Pharmaceutical Co., Ltd. | Freeze-dried preparation of n-¬o-(p-pivaloyloxybenzenesulfonylamino)benzoyl|glycine monosodium salt tetrahydrate and a process for the maufacture thereof |
| US20050101633A1 (en) * | 2001-05-17 | 2005-05-12 | Takeharu Tonai | Remedial agent for myelopathic disease |
| TW200519080A (en) * | 2003-10-03 | 2005-06-16 | Ono Pharmaceutical Co | Agent containinf (2R)-2-propyloctanic acid as effective component |
| CA2707484C (en) | 2007-12-04 | 2021-08-10 | Remedy Pharmaceuticals, Inc. | Improved formulations and methods for lyophilization and lyophilates provided thereby |
| KR101247137B1 (ko) * | 2011-03-23 | 2013-04-01 | 주식회사 엠씨켐 | Ｎ-[ｏ-(ｐ-피발로일옥시벤젠술포닐아미노)벤조일]글리신의 신규 제조 방법 및 그 모노나트륨염ㆍ4 수화물의 동결 건조 제제의 제조 방법 |
| KR101366706B1 (ko) | 2012-12-06 | 2014-02-24 | 상명대학교서울산학협력단 | Ｎ-[ｏ-(ｐ-피발로일옥시벤젠술포닐아미노)벤조일]글리신의 신규 제조 방법 및 그 모노나트륨염ㆍ4 수화물의 동결 건조 제제의 제조 방법 |
| CN104107172B (zh) * | 2013-04-18 | 2017-11-28 | 上海汇伦生命科技有限公司 | 西维来司钠注射用冻干粉的制备方法 |
| CN114681435A (zh) * | 2020-12-31 | 2022-07-01 | 上海汇伦生物科技有限公司 | 吸入用药物组合物 |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPH0320253A (ja) | 1988-06-13 | 1991-01-29 | Ono Pharmaceut Co Ltd | ピバル酸 ｐ―置換フェニルエステル誘導体、それらの製造方法およびそれらを有効成分として含有するエラスターゼ阻害剤 |
| CA1340191C (en) | 1988-06-13 | 1998-12-15 | Katsuhiro Imaki | Derivatives of p-substituted phenyl ester of pivalic acid |
| IT1242642B (it) * | 1990-04-17 | 1994-05-16 | Alfa Wassermann Spa | Formulazioni iniettabili contenenti naproxen sale sodico. |
| JP3020253B2 (ja) | 1990-05-02 | 2000-03-15 | 松下電工株式会社 | 配線器具の取付枠への取付構造 |
| EP0539223A1 (en) | 1991-10-25 | 1993-04-28 | Ono Pharmaceutical Co., Ltd. | Glycine derivative monosodium salt tetrahydrate having an inhibitory effect on elastase |
| JPH05194366A (ja) | 1991-10-25 | 1993-08-03 | Ono Pharmaceut Co Ltd | グリシン誘導体・モノナトリウム塩・４水和物、その製造方法、それを含有する薬剤および該誘導体の中間体の製造方法 |
| JP3193597B2 (ja) | 1995-07-28 | 2001-07-30 | 小野薬品工業株式会社 | グリシン誘導体の製造方法 |
| AU5528299A (en) | 1998-09-15 | 2000-04-03 | Naeja Pharmaceutical Inc. | Combined therapy for treatment of inflammation using elastase inhibitor(s) and antibacterial agent(s) |
| AU6870800A (en) * | 1999-09-06 | 2001-04-10 | Ono Pharmaceutical Co. Ltd. | Preventive and therapeutic agents for eye diseases |
-
2001
- 2001-06-18 US US09/882,335 patent/US6552082B2/en not_active Expired - Fee Related
- 2001-06-19 NZ NZ512486A patent/NZ512486A/en not_active IP Right Cessation
- 2001-06-21 TW TW090115094A patent/TWI246925B/zh not_active IP Right Cessation
- 2001-06-22 CA CA2351273A patent/CA2351273C/en not_active Expired - Fee Related
- 2001-06-27 NO NO20013223A patent/NO330296B1/no not_active IP Right Cessation
- 2001-06-27 DK DK01305556T patent/DK1166773T3/da active
- 2001-06-27 ES ES01305556T patent/ES2215856T3/es not_active Expired - Lifetime
- 2001-06-27 DE DE60101979T patent/DE60101979T2/de not_active Expired - Lifetime
- 2001-06-27 KR KR1020010036853A patent/KR100725076B1/ko active IP Right Grant
- 2001-06-27 EP EP01305556A patent/EP1166773B1/en not_active Expired - Lifetime
- 2001-06-27 TR TR2004/00585T patent/TR200400585T4/xx unknown
- 2001-06-27 AT AT01305556T patent/ATE259218T1/de active
- 2001-06-27 PT PT01305556T patent/PT1166773E/pt unknown
- 2001-06-27 AU AU54092/01A patent/AU782838B2/en not_active Ceased
- 2001-06-28 RU RU2001118162/15A patent/RU2272623C2/ru not_active IP Right Cessation
- 2001-06-28 MX MXPA01006698A patent/MXPA01006698A/es active IP Right Grant
- 2001-06-28 BR BRPI0102604-6A patent/BR0102604B1/pt not_active IP Right Cessation
- 2001-06-28 HU HU0102699A patent/HUP0102699A2/hu unknown
- 2001-06-29 CN CNB011254688A patent/CN1263736C/zh not_active Expired - Fee Related
Also Published As
| Publication number | Publication date |
|---|---|
| KR100725076B1 (ko) | 2007-06-08 |
| RU2272623C2 (ru) | 2006-03-27 |
| NO20013223D0 (no) | 2001-06-27 |
| ES2215856T3 (es) | 2004-10-16 |
| DE60101979D1 (de) | 2004-03-18 |
| NO20013223L (no) | 2001-12-31 |
| AU782838B2 (en) | 2005-09-01 |
| NZ512486A (en) | 2001-12-21 |
| KR20020002242A (ko) | 2002-01-09 |
| US20020022738A1 (en) | 2002-02-21 |
| BR0102604A (pt) | 2002-02-13 |
| CA2351273A1 (en) | 2001-12-29 |
| TR200400585T4 (tr) | 2004-04-21 |
| CN1263736C (zh) | 2006-07-12 |
| BR0102604B1 (pt) | 2012-06-26 |
| CN1341591A (zh) | 2002-03-27 |
| DE60101979T2 (de) | 2005-01-05 |
| AU5409201A (en) | 2002-03-28 |
| CA2351273C (en) | 2010-09-07 |
| MXPA01006698A (es) | 2004-07-30 |
| US6552082B2 (en) | 2003-04-22 |
| HU0102699D0 (en) | 2001-08-28 |
| PT1166773E (pt) | 2004-05-31 |
| TWI246925B (en) | 2006-01-11 |
| DK1166773T3 (da) | 2004-06-07 |
| ATE259218T1 (de) | 2004-02-15 |
| EP1166773A1 (en) | 2002-01-02 |
| HUP0102699A2 (en) | 2002-06-29 |
| EP1166773B1 (en) | 2004-02-11 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| RU2176507C2 (ru) | Пероральные жидкие композиции, содержащие алендронат | |
| NO344885B1 (no) | En stabil sammensetning omfattende et benanabolt protein, nemlig en PTHrP-analog, og anvendelser derav | |
| JP3723857B2 (ja) | ヒト成長ホルモン含有水性医薬組成物 | |
| NO175406B (no) | Fremgangsmåte ved fremstilling av piroxam i vandig opplösning | |
| KR20040063913A (ko) | 2-(4-이소부틸페닐)프로피온산의 약학 조성물 | |
| US20070203357A1 (en) | Freeze-dried product of n-[o-(p-pivaloyloxy benzenesulfonylamino) benzoyl]glycine monosodium salt tetra-hydrate and a process for the manufacture thereof | |
| JPH08245417A (ja) | 鼻内投与のための薬学的非無機塩類液剤 | |
| US4836957A (en) | Stabilized active forms of vitamin D3 | |
| NO330296B1 (no) | Opplosning av N-[O-(p-pivaloyloksybenzensulfonylamino)-benzoyl]glycinmononatriumsalt-tetrahydrat og medisinsk produkt | |
| JPS638339A (ja) | 非経口投与用医薬組成物 | |
| CN105596302A (zh) | 一种乌司他丁冻干粉制剂及其制备方法 | |
| US5955456A (en) | Injectable pharmaceutical composition comprising ursodesoxycholic acid or tauroursodesoxycholic acid, a strong base and tromethamol | |
| NO322334B1 (no) | Lyofilisert preparat av human benmorfogenetisk faktor MP52, og fremgangsmate for fremstilling av et lyofilisert preparat av human benmorfogenetisk faktor MP52 | |
| JPS61126014A (ja) | 経鼻投与用水性液剤 | |
| JPWO2004098614A1 (ja) | メチルコバラミン含有凍結乾燥製剤及びその製造方法 | |
| WO2002017932A1 (fr) | Preparations d'oct | |
| JP2023522890A (ja) | トラベクテジンおよびアミノ酸を含む組成物 | |
| JP3956654B2 (ja) | Ｎ−［ｏ−（ｐ−ピバロイルオキシベンゼンスルホニルアミノ）ベンゾイル］グリシン・モノナトリウム塩・４水和物含有溶液および製剤 | |
| JP3535537B2 (ja) | 静脈注射剤 | |
| JPH09104627A (ja) | アパファントを主薬とする水性点眼剤 | |
| MXPA06014386A (es) | Solucion acuosa de risperidona para administracion oral. | |
| WO2004108061A2 (en) | Stable injectable pharmaceutical composition of thiopental; method for stabilizing aqueous solutions of thiopental and, use of thiopental for producing a medicament | |
| JPH02202822A (ja) | 肝細胞増殖促進剤 | |
| AU2018327614A1 (en) | Composition for calcium supplementation | |
| JPH10298102A (ja) | カルシトニン注射液 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| MM1K | Lapsed by not paying the annual fees |